UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine
Abstract
Introduction: Migraine is a primary headache disorder, which leads to diminished health-related quality of life (HRQoL). There is limited evidence assessing efficacy of cannabis-based medicinal products (CBMPs) for migraine. This study investigates the efficacy and safety of CBMPs to treat migraine headache using validated patient-reported outcome measures.
Methods: This case series utilizes data from the UK Medical Cannabis Registry. Primary outcomes included changes in Headache Impact Test 6 (HIT-6), Migraine Disability Assessment Test (MIDAS), Generalized Anxiety Disorder 7 (GAD-7), Single Item Sleep Quality Scale (SQS), and EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) from baseline up to 24 months. Adverse events (AEs) and their severity were recorded. A p-value < 0.050 was statistically significant.
Results: Two hundred and three adult patients met inclusion criteria. Improvements at all intervals up to 24 months, relative to baseline, were observed in the HIT-6, GAD-7, SQS, and EQ-5D-5L (p < 0.010) and up to 12 months in the MIDAS (p < 0.050). Female sex (odds ratio [OR] 0.48, 95% confidence interval [CI] 0.23-0.98, p = 0.046) and a bottom quartile THC dose (OR 0.25, CI 0.06-0.93, p = 0.047) were negative predictors of MIDAS improvement. One in seven (n = 31; 15.27%) patients reported 249 AEs (n = 110, 44.18% mild; n = 79, 31.73% moderate; n = 57, 26.91% severe; n = 3, 1.20% life-threatening).
Discussion: CBMPs were associated with improvements in HRQoL measures up to 2…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 110 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.